Secondary Cancers Resurface In Updated Revlimid Maintenance Trial Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial investigators proclaim the drug's benefits outweigh its risks and predict maintenance will become the standard of care in multiple myeloma, but investors remain unconvinced.